Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

AstraZeneca Spinout Venture Part 2

Reference number
Coordinator AstraZeneca AB - AstraZeneca AB, Södertälje
Funding from Vinnova SEK 5 570 687
Project duration January 2017 - December 2019
Status Completed

Purpose and goal

The Spinn-Out project part two intended to pilot 1 or 2 projects based on the business principles derived from part one of the project. The aim was to identify a mechanism for the release of shelved innovation from large corporations.

Expected results and effects

A series of tentative projects were evaluated and reformatted to suit SME perspectives and the project chosen as the pilot resulted in the formation and capitalization of OnDosis AB.

Planned approach and implementation

** Denna text är maskinöversatt ** In part two of the project,potential projects were evaluated, in total nine different projevcts were assessed regarding - Innovation - Marketing potential - Intellectual property - Potential conflict of interest - Development costs, existing and future - Competence Requirements for the further development of the projektet - Interest from 6 different VC companies I cooperation with investors business plans were prepared as well as the recruitment of the CEO and key personnel.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 4 March 2022

Reference number 2017-02169

Page statistics